Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy

Background The current study aimed to evaluate the serum pretreatment lactate dehydrogenase (LDH) and overall survival (OS) in small cell lung cancer (SCLC) patients who received first‐line platinum‐containing chemotherapy. Methods A total of 234 SCLC patients, who received first‐line platinum‐based...

Full description

Bibliographic Details
Main Authors: Man He, Xiaorui Chi, Xinyan Shi, Yang Sun, Xue Yang, Leirong Wang, Bingrui Wang, Hongmei Li
Format: Article
Language:English
Published: Wiley 2021-12-01
Series:Thoracic Cancer
Subjects:
Online Access:https://doi.org/10.1111/1759-7714.13581
_version_ 1819202846555373568
author Man He
Xiaorui Chi
Xinyan Shi
Yang Sun
Xue Yang
Leirong Wang
Bingrui Wang
Hongmei Li
author_facet Man He
Xiaorui Chi
Xinyan Shi
Yang Sun
Xue Yang
Leirong Wang
Bingrui Wang
Hongmei Li
author_sort Man He
collection DOAJ
description Background The current study aimed to evaluate the serum pretreatment lactate dehydrogenase (LDH) and overall survival (OS) in small cell lung cancer (SCLC) patients who received first‐line platinum‐containing chemotherapy. Methods A total of 234 SCLC patients, who received first‐line platinum‐based chemotherapy between 2013 and 2018, were retrospectively analyzed. The data of hematological characteristics, age, gender, ECOG score, staging, metastatic site, smoking history, chemotherapy cycle, thoracic radiotherapy and hyponatremia were collected. Overall survival was calculated using the Kaplan‐Meier method. The statistically significant factors in the univariate analysis were selected for the multivariate COX model analysis. Results Age, ECOG score, stage, thoracic radiotherapy, hyponatremia, liver metastasis, brain metastasis, bone metastasis, LDH, NSE and neutrophil‐to‐lymphocyte ratio (NLR) were closely correlated to OS in the univariate analysis. Furthermore, the multivariate analysis revealed that age (<65 years), ECOG score (<2 points), limited‐stage (LD), thoracic radiotherapy and LDH <215.70 U/L were the independent prognostic factors for survival. The median OS time was worse for patients with LDH ≥215.70 U/L. In the subgroup analysis, LDH ≥215.70 U/L was significant for survival in both limited and extensive disease. Patients who achieved CR + PR in the first‐line treatment had lower initial LDH levels. It was found that the pretreatment LDH increased the incidence of patients with liver metastasis. Conclusions Positive independent prognostic factors for SCLC patients were age < 65 years old, ECOG score < 2 points, LD‐SCLC, and pretreatment LDH <215.70 U/L. These factors may be useful for stratifying patients with SCLC for treatment approaches. Key points Significant findings of the study Age < 65 years old, ECOG score < 2 points, LD‐SCLC, and pretreatment LDH <215.70 U/L are the positive independent prognostic factors for SCLC patients. What this study adds The current study provided more references for SCLC diagnosis and treatment and determined more factors for stratifying patients with SCLC for treatment approaches.
first_indexed 2024-12-23T04:10:31Z
format Article
id doaj.art-47ae4f268c6a44c288667897141c8b59
institution Directory Open Access Journal
issn 1759-7706
1759-7714
language English
last_indexed 2024-12-23T04:10:31Z
publishDate 2021-12-01
publisher Wiley
record_format Article
series Thoracic Cancer
spelling doaj.art-47ae4f268c6a44c288667897141c8b592022-12-21T18:00:31ZengWileyThoracic Cancer1759-77061759-77142021-12-0112233101310910.1111/1759-7714.13581Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapyMan He0Xiaorui Chi1Xinyan Shi2Yang Sun3Xue Yang4Leirong Wang5Bingrui Wang6Hongmei Li7Department of Oncology The Affiliated Hospital of Qingdao University Qingdao ChinaDepartment of Oncology The Affiliated Hospital of Qingdao University Qingdao ChinaDepartment of Oncology The Affiliated Hospital of Qingdao University Qingdao ChinaDepartment of Oncology The Affiliated Hospital of Qingdao University Qingdao ChinaDepartment of Oncology The Affiliated Hospital of Qingdao University Qingdao ChinaDepartment of Oncology The Affiliated Hospital of Qingdao University Qingdao ChinaDepartment of Oncology The Affiliated Hospital of Qingdao University Qingdao ChinaDepartment of Oncology The Affiliated Hospital of Qingdao University Qingdao ChinaBackground The current study aimed to evaluate the serum pretreatment lactate dehydrogenase (LDH) and overall survival (OS) in small cell lung cancer (SCLC) patients who received first‐line platinum‐containing chemotherapy. Methods A total of 234 SCLC patients, who received first‐line platinum‐based chemotherapy between 2013 and 2018, were retrospectively analyzed. The data of hematological characteristics, age, gender, ECOG score, staging, metastatic site, smoking history, chemotherapy cycle, thoracic radiotherapy and hyponatremia were collected. Overall survival was calculated using the Kaplan‐Meier method. The statistically significant factors in the univariate analysis were selected for the multivariate COX model analysis. Results Age, ECOG score, stage, thoracic radiotherapy, hyponatremia, liver metastasis, brain metastasis, bone metastasis, LDH, NSE and neutrophil‐to‐lymphocyte ratio (NLR) were closely correlated to OS in the univariate analysis. Furthermore, the multivariate analysis revealed that age (<65 years), ECOG score (<2 points), limited‐stage (LD), thoracic radiotherapy and LDH <215.70 U/L were the independent prognostic factors for survival. The median OS time was worse for patients with LDH ≥215.70 U/L. In the subgroup analysis, LDH ≥215.70 U/L was significant for survival in both limited and extensive disease. Patients who achieved CR + PR in the first‐line treatment had lower initial LDH levels. It was found that the pretreatment LDH increased the incidence of patients with liver metastasis. Conclusions Positive independent prognostic factors for SCLC patients were age < 65 years old, ECOG score < 2 points, LD‐SCLC, and pretreatment LDH <215.70 U/L. These factors may be useful for stratifying patients with SCLC for treatment approaches. Key points Significant findings of the study Age < 65 years old, ECOG score < 2 points, LD‐SCLC, and pretreatment LDH <215.70 U/L are the positive independent prognostic factors for SCLC patients. What this study adds The current study provided more references for SCLC diagnosis and treatment and determined more factors for stratifying patients with SCLC for treatment approaches.https://doi.org/10.1111/1759-7714.13581LDHOSprognosisSCLC
spellingShingle Man He
Xiaorui Chi
Xinyan Shi
Yang Sun
Xue Yang
Leirong Wang
Bingrui Wang
Hongmei Li
Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
Thoracic Cancer
LDH
OS
prognosis
SCLC
title Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
title_full Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
title_fullStr Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
title_full_unstemmed Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
title_short Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
title_sort value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small cell lung cancer patients treated with first line platinum containing chemotherapy
topic LDH
OS
prognosis
SCLC
url https://doi.org/10.1111/1759-7714.13581
work_keys_str_mv AT manhe valueofpretreatmentserumlactatedehydrogenaseasaprognosticandpredictivefactorforsmallcelllungcancerpatientstreatedwithfirstlineplatinumcontainingchemotherapy
AT xiaoruichi valueofpretreatmentserumlactatedehydrogenaseasaprognosticandpredictivefactorforsmallcelllungcancerpatientstreatedwithfirstlineplatinumcontainingchemotherapy
AT xinyanshi valueofpretreatmentserumlactatedehydrogenaseasaprognosticandpredictivefactorforsmallcelllungcancerpatientstreatedwithfirstlineplatinumcontainingchemotherapy
AT yangsun valueofpretreatmentserumlactatedehydrogenaseasaprognosticandpredictivefactorforsmallcelllungcancerpatientstreatedwithfirstlineplatinumcontainingchemotherapy
AT xueyang valueofpretreatmentserumlactatedehydrogenaseasaprognosticandpredictivefactorforsmallcelllungcancerpatientstreatedwithfirstlineplatinumcontainingchemotherapy
AT leirongwang valueofpretreatmentserumlactatedehydrogenaseasaprognosticandpredictivefactorforsmallcelllungcancerpatientstreatedwithfirstlineplatinumcontainingchemotherapy
AT bingruiwang valueofpretreatmentserumlactatedehydrogenaseasaprognosticandpredictivefactorforsmallcelllungcancerpatientstreatedwithfirstlineplatinumcontainingchemotherapy
AT hongmeili valueofpretreatmentserumlactatedehydrogenaseasaprognosticandpredictivefactorforsmallcelllungcancerpatientstreatedwithfirstlineplatinumcontainingchemotherapy